Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

63 participants · First posted Jul 9, 2018

Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

7 participants · First posted Jul 11, 2022

European Stop Tyrosine Kinase Inhibitor Study

868 participants · First posted May 10, 2012

Tyrosine(Premasol, Clinimix E 2.75/5, Aminosyn-PF 7%, Primene, Clinimix 2.75/5, Trophamine 10 %, Plenamine, Olimel, Prosol, Clinisol 15, Periolimel, Travasol 10)

C₉H₁₁NO₃

Axl tyrosine kinase inhibitors (SuperGen)

CATALO NATURALS (AUSTRALIA) PTY LTD

Australia

Inhibikase Therapeutics

United States

Exelixis, Inc.

United States

Inebilizumab Shows Promise in Myasthenia Gravis, Phase 3 Data Suggests

NMD Pharma Presents Preclinical Data on ClC-1 Ion Channel Inhibition for MuSK Myasthenia Gravis Treatment

argenx Advances ARGX-119 to Registrational Study for Ultra-Rare Congenital Myasthenic Syndromes